RPRX
Royalty Pharma Plc - USData as of 2026 Q2 (06-30) · 13F snapshot
Summary
Royalty Pharma Plc - US (RPRX) is held as common stock by 6 tracked hedge-fund managers, with a combined reported value of ~$237.71M; the largest are Renaissance Technologies, Ken Griffin, Paul Tudor Jones. 2 tracked managers also disclosed PUT or CALL positions, reported separately below. This quarter: 2 new, 1 added, 3 trimmed. 4 public STOCK Act / OGE trade disclosures are on record. Data as of 2026 Q2, from public SEC 13F filings, delayed up to ~45 days.
Attention · MediumThis quarter · Mixed
Common-stock holders62 also report options
Congress trades4
Price$58.37vs quarter-end+4.10%
Sectors0
This quarter's moves
Top holderNew2
Added1
Trimmed / sold3
Renaissance TechnologiesCommon-stock positions
PUT and CALL disclosures are excluded from these holder counts and values.
| Investor | Value | % of portfolio | Action |
|---|
PUT / CALL disclosures
Reported separately: 13F option values are not common-stock ownership and do not reveal the full strategy or economic exposure.
Value $12.77M— of portfolio227,7002026 Q2
Value $459.8K— of portfolio8,2002026 Q2
Value $381.3K— of portfolio6,8002026 Q2
| Investor | Value | % of portfolio | Action |
|---|---|---|---|
| Ken GriffinCALL | $12.77M | — | — |
| Ken GriffinPUT | $459.8K | — | — |
| Izzy EnglanderPUT | $381.3K | — | — |
Public SEC 13F filings may appear up to 45 days after quarter-end; STOCK Act / OGE trade filings are generally due within 45 days but may be late. Partial data only — research, not investment advice.